Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LifeCycle Pharma has been awarded DKK3.899.289 grant from the Danish National Advanced Technology Foundation for its collaborative work with Herlev Hospital to develop an oral chemotherapeutic agent.
Subscribe to our email newsletter
A research conducted by LifeCycle Pharma demonstrated that certain types of intravenous chemotherapy can be modified, utilizing LifeCycle Pharma technologies, to pill-based therapy.
Herlev Hospital Oncology Department chief physician Dorte Nielsen said Herlev Hospital looks forward to utilizing their expertise in chemotherapy to improve cancer treatment for the benefit of their patients.
LifeCycle Pharma Pharmaceutical Development & CMC senior vice president Peter Nielsen said they are very pleased with the grant from the Advanced Technology Foundation which will enable them to utilize their technologies and extensive experience in working with hard-to-dose drugs in oral form to develop novel chemotherapy products for the benefit of patients and the society.